A randomized double blind, placebo-controlled clinical trial with oral n-acetylcysteine in systemic sclerosis patients and assessment of skin blood flow of the hands with laser Doppler perfusion imaging
Oral N-acetylcysteine in the Treatment of Raynaud's Phenomenon Secondary to Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial
Foundation for the support for research in the state of Sao Paulo
40 participants
Aug 25, 2008
Interventional
Conditions
Summary
analyze the effect of oral N-acetylcysteine on microcirculation by laser Doppler perfusion imaging in systemic sclerosis patients
Eligibility
Inclusion Criteria1
- Raynaud phenomenon secondary to systemic sclerosis with pain
Exclusion Criteria1
- smokers and diabetes
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
participants will receive capsules with n-acetylcysteine 600 mg three applications per day orally for 4 weeks to be provided by a developer who did not attend the previous steps
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000114044